19 C
Vientiane
Tuesday, February 25, 2025
spot_img

Cision PR Newswire

CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA

Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The GEMSTONE-303 study results support sugemalimab in combination with chemotherapy as a new standard first-line treatment for patients with PD-L1 combined positive score (CPS) ≥5. ...

Lessons from Japan’s AMR Response for the Global Community

https://iris.who.int/handle/10665/380481 TOKYO, Feb. 25, 2025 /PRNewswire/ -- World Health Organization (WHO) Regional Office...

JACKY CHEUNG BREAKS RECORD WITH 1000 SHOWS ACROSS 10 TOURS, A MILESTONE IN CHINESE MUSIC HISTORY

BEIJING, Feb. 25, 2025 /PRNewswire/ -- Jacky Cheung, known as the "God of Songs"...

Meizu to debut AI full ecosystem products at MWC 2025

BARCELONA, Spain, Feb. 25, 2025 /PRNewswire/ -- The Mobile World Congress (MWC 2025) will...

Bright Scholar Schedules Unaudited Financial Results for the First Quarter of Fiscal 2025 Ended November 30, 2024

CAMBRIDGE, England and FOSHAN, China, Jan. 23, 2025 /PRNewswire/ -- Bright Scholar Education Holdings Limited ("Bright Scholar," the "Company," "we" or "our") (NYSE: BEDU),...

Pictor Biotech Inc. (d.b.a. SOLARBIOTECH), GPC Bio, and Eleszto Genetika Announce Strategic Unification

NORTON, Va., LA ROCHELLE, France and BUDAPEST, Hungary, Jan. 23, 2025 /PRNewswire/ -- Today, SOLARBIOTECH, GPC Bio, and Eleszto Genetika proudly announced their acquisition and strategic...

Infinitus Honored as “China Top Employer” for Five Consecutive Years

GUANGZHOU, China, Jan. 23, 2025 /PRNewswire/ -- On the evening of January 16, 2025, the annual "China Top Employers" list was announced. Infinitus secured...